In July this year, Mankind Pharma announced that it will fully acquire Bharat Serums and Vaccines from private equity firm Advent International for around Rs 13,630 crore.
The Competition Commission of India (CCI) on October 1 approved the proposed acquisition of Bharat Serums and Vaccines by Mankind Pharma for Rs 13,630 crore.
Listed firm Mankind Pharma is engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical finished dosage formulations. Mankind, through its subsidiaries also, involved in the manufacturing and sale of active pharmaceutical ingredients (APIs), pharmaceutical intermediaries, and packaging products for pharmaceutical products.
Bharat Serums and Vaccines Ltd (BSV) is engaged in research, development, licensing, manufacturing, importing, exporting, marketing and distribution of pharmaceutical formulations/ FDFs, APIs, food and health supplements.
BSV is also a biopharmaceutical leader in women's healthcare, assisted reproductive treatment, critical care and emergency medicine.
In July this year, Mankind Pharma announced that it will fully acquire Bharat Serums and Vaccines from private equity firm Advent International for around Rs 13,630 crore.
Source: Moneycontrol
